Amid intense scrutiny, lawsuits, harsh federal sanctions, and criminal probes, Theranos CEO and founder Elizabeth Holmes will finally present data on her struggling company’s blood testing technology.

She will present today at 4:30pm in a special session of the American Association for Clinical Chemistry’s annual conference, being held this year in Philadelphia.

The presentation couldn’t come at a more dire time for the company, which has seen a staggering number of setbacks in recent months. The most prominent of those include federal regulators banning Holmes from the clinical blood testing business for at least two years and shuttering one of the company’s labs. Theranos has seen its valuation drop from $9 billion to around $800 million. Its commercial partner, Walgreens, also backed out of its contract and shut down 40 of the companies' joint “wellness centers.”

The timing of the presentation may appear as a hasty, desperate attempt to quell critics and restore some validity to the company, however Holmes has been on AACC’s docket for months.

Based on the abstract, her presentation will outline Therano’s technology and methods, said to be able to accurately perform hundreds of tests using blood from finger pricks, rather than vein draws—a claim that has been seen as dubious based on an independent study and federal regulators’ reviews.

Holmes’ presentation aims to refute those criticisms by providing “reproducibility and correlation data for various tests comparing Theranos' capillary collection and storage device with traditional venipuncture methods.” She will also present “data to demonstrate the precision and accuracy of these chemistry, immunochemistry, hematology, and molecular assays (traditionally performed on separate instruments) using their analytical testing platform, including a novel molecular test for the Zika virus.”

The plan to have Holmes speak at the AACC’s annual conference has spurred discomfort among its 8,000 or so members. The AACC, which saw its start in 1948, is a “global scientific and medical professional organization dedicated to clinical laboratory science,” according to the association’s website. Many sources have reported that some members see Holmes’ presentation as bringing negative attention to their respectable scientific association. AACC member Geoff Baird, a clinical pathologist at the University of Washington, told STAT that among AACC colleagues, Theranos is “uniformly viewed as a fraud.”

In an updated press release, AACC CEO Janet Kreizman stated that "there is no better place" for Holmes to give a presentation because it will allow AACC's distinguished members to vet the data. Still, the press release emphasized that it had no links to the company, stating: